Protara Therapeutics
TARA
31 hedge funds and large institutions have $14.9M invested in Protara Therapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.44% less ownership
Funds ownership: 52.69% → 50.25% (-2.4%)
6% less funds holding
Funds holding: 33 → 31 (-2)
6% less capital invested
Capital invested by funds: $16M → $14.9M (-$1.02M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
+$119K |
| 2 |
Renaissance Technologies
New York
|
+$84.7K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$81K |
| 4 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
+$21K |
| 5 |
VF
Virtu Financial
New York
|
+$8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
-$461K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$244K |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$234K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$43.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $1K | -$7.49K | -2,210 | -90% |
|
27
UBS Group
Zurich,
Switzerland
| $1K | -$3.5K | -1,032 | -81% |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| $1K | -$454 | -134 | -35% |
|
29
Wells Fargo
San Francisco,
California
| $1K | -$27 | -8 | -1% |
|
|
APA
30
American Portfolios Advisors
Holbrook,
New York
| $296 | – | – | – |
|
|
DAM
31
DLD Asset Management
New York
| – | -$461K | -157,349 | Closed |
|
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$47K | -15,969 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$5K | -1,807 | Closed |
|
34
JP Morgan Chase
New York
| – | -$1K | -352 | Closed |
|
TARA Hedge Fund Activity: Q3 2022 in Review
31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2022, worth a combined $14.9M — down 6.4% from $16M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TARA and 2 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 3 added.
The largest buyer was Privium Fund Management (UK), opening a new position worth an estimated $119K. The largest seller was DLD Asset Management, exiting entirely with an estimated $461K sold.
- 31 institutional investors held Protara Therapeutics (TARA) as of Q3 2022, down from 33 in Q2 2022.
- Funds reported $14.9M of Protara Therapeutics stock for Q3 2022, down 6.4% quarter-over-quarter.
- 2 funds opened new Protara Therapeutics positions in Q3 2022 and 4 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q3 2022 was Privium Fund Management (UK), an estimated $119K added.
- The largest Protara Therapeutics seller in Q3 2022 was DLD Asset Management, an estimated $461K sold.
Based on aggregated 13F filings for Q3 2022.